[go: up one dir, main page]

GB201108272D0 - Methods relating to HCMV infected cells - Google Patents

Methods relating to HCMV infected cells

Info

Publication number
GB201108272D0
GB201108272D0 GB201108272A GB201108272A GB201108272D0 GB 201108272 D0 GB201108272 D0 GB 201108272D0 GB 201108272 A GB201108272 A GB 201108272A GB 201108272 A GB201108272 A GB 201108272A GB 201108272 D0 GB201108272 D0 GB 201108272D0
Authority
GB
United Kingdom
Prior art keywords
infected cells
hcmv
methods relating
hcmv infected
mrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201108272A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GB201108272A priority Critical patent/GB201108272D0/en
Publication of GB201108272D0 publication Critical patent/GB201108272D0/en
Priority to PCT/GB2012/051094 priority patent/WO2012156733A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention relates to the identification and/or elimination of Human Cytomegalovirus (HCMV) infected cells from mammalian cell populations by determining the expression of multidrug resistance-associated protein-1 (MRP-1) and/or other UL138 modulated cell surface proteins. HCMV infected cells may be identified through alterations in the expression MRP-1 and/or other UL138 modulated cell surface proteins, and separated. Mammalian cell populations depleted of HCMV infected cells may be useful, for example in transplants, such as bone marrow transplants.
GB201108272A 2011-05-17 2011-05-17 Methods relating to HCMV infected cells Ceased GB201108272D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201108272A GB201108272D0 (en) 2011-05-17 2011-05-17 Methods relating to HCMV infected cells
PCT/GB2012/051094 WO2012156733A1 (en) 2011-05-17 2012-05-16 Detection and depletion of hcmv infected cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201108272A GB201108272D0 (en) 2011-05-17 2011-05-17 Methods relating to HCMV infected cells

Publications (1)

Publication Number Publication Date
GB201108272D0 true GB201108272D0 (en) 2011-06-29

Family

ID=44260678

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201108272A Ceased GB201108272D0 (en) 2011-05-17 2011-05-17 Methods relating to HCMV infected cells

Country Status (2)

Country Link
GB (1) GB201108272D0 (en)
WO (1) WO2012156733A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2886552A1 (en) * 2013-12-17 2015-06-24 Ecole Polytechnique Federale de Lausanne (EPFL) Methods for purging isolated organs and cells from latent human cytomegalovirus
CN107817340A (en) * 2017-08-01 2018-03-20 东南大学 A kind of kit of SERS technology for detection Mdr-p and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5783383A (en) * 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
AU783502B2 (en) * 1999-11-24 2005-11-03 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
AU2002247655A1 (en) * 2001-01-26 2002-08-06 Epidauros Biotechnologies Ag Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
WO2002062956A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Chemomagnetic retrieval of cmv and cmv infected cells
WO2007038316A2 (en) * 2005-09-23 2007-04-05 The Trustees Of Princeton University Human cytomegalovirus latency promoting genes, related virus variants and methods of use

Also Published As

Publication number Publication date
WO2012156733A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
IL276146B1 (en) Laboratory methods for increasing the vitality of the cells of the immune system
MX2012011779A (en) 5-position modified pyrimidines and their use.
GEP201706605B (en) Antibodies for epidermal growth factor receptor 3 (her3)
EP2547346A4 (en) System for purifying certain cell populations in blood or bone marrow by depleting others
EP4368715A3 (en) Nucleic acid sequence analysis from single cells
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
PH12013501849A1 (en) Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2012018933A3 (en) Reprogramming immortalized b cells
IN2014DN07531A (en)
EA201491144A1 (en) METHOD OF FLOCULATION
UY34663A (en) NUCLEIC ACID AND RECOMBINANT PROTEIN OF THE AXMI345 ENDOTOXINE GENE, VECTORS, CELLS, COMPOSITIONS AND METHODS TO PROTECT PLANTS
MA38632B1 (en) Anti-transferrin receptor antibodies and methods of use
GB201020995D0 (en) Biological materials and uses thereof
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
NZ586576A (en) Improved mammalian expression vectors and uses thereof
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
IL247447B (en) An oocyte comprising exogenous, autologous functional mitochondria obtained from an oogonial stem cell (osc) or the progeny of an osc
AR093446A1 (en) ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE
WO2011021194A3 (en) Pericyte progenitor cells and methods of generating and using same
GB201205769D0 (en) Methods for preparing samples for nucleic acid amplification
WO2010120518A3 (en) Sperm cell separation methods and compositions containing sperm cell targeting ligands for use therein
WO2013166338A3 (en) Cell capture system and use thereof
AU2012209627A1 (en) Composition for detecting proteins containing tyrosine oxide-coupled biomaterial
SG10201807572PA (en) Robust antibody purification

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)